News from pharmacyclics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 18, 2014, 16:05 ET

Pharmacyclics Appoints Chief Commercial Officer

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer.  Ms....

Jul 31, 2014, 16:04 ET

Pharmacyclics Reports Second Quarter 2014 Results

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended June 30,...

Jul 28, 2014, 19:02 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...

Jul 28, 2014, 13:18 ET

U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA® (ibrutinib) regular...

Jul 26, 2014, 17:32 ET

Positive Beurteilung der Europäischen Arzneimittel-Agentur: empfiehlt Zulassung von IMBRUVICA™ (Ibrutinib) zur Behandlung zweier Blutkrebsformen

 Pharmacyclics Switzerland GmbH, eine Tochtergesellschaft von Pharmacyclics Inc. (NASDAQ: PCYC), verkündete heute, dass der Ausschuss...

Jul 26, 2014, 16:09 ET

L'Agence européenne des médicaments (EMA) publie un avis positif, recommande l'homologation de l'IMBRUVICA™ (ibrutinib) pour le traitement de deux cancers du sang

 Pharmacyclics Switzerland GmbH, une filiale de Pharmacyclics, Inc. (NASDAQ : PCYC), a annoncé aujourd'hui que le Comité...

Jul 26, 2014, 11:04 ET

EMA recomienda la aprobación de IMBRUVICA™ para el tratamiento de dos cánceres sanguíneos

-- La Agencia Europea del Medicamento (EMA) emite una opinión positiva, recomendando la aprobación de IMBRUVICA™ (ibrutinib)...

Jul 25, 2014, 08:52 ET

European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Jun 09, 2014, 08:00 ET

Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New...

May 31, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA® (ibrutinib) will be featured in...

May 31, 2014, 08:05 ET
May 31, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA®(ibrutinib) in combination with the anti-CD20 antibody, ofatumumab,...

May 20, 2014, 08:00 ET

Pharmacyclics appoints Gregory R. Wade to lead Business Development

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice...

May 14, 2014, 18:22 ET

Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced IMBRUVICA® (ibrutinib) will be featured in ten abstracts, including both company-sponsored...

May 02, 2014, 08:00 ET

Pharmacyclics Reports First Quarter 2014 Results

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31,...

Apr 25, 2014, 10:45 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...

Apr 21, 2014, 11:45 ET

Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE™) study of single agent...

Apr 08, 2014, 08:00 ET

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Feb 20, 2014, 16:01 ET

Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December...

Feb 14, 2014, 15:45 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Fourth Quarter and Year End 2013

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...